MRK
Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$143.67
−1.56%Aug 29, 2026, 21:30 UTC
The Australian Federal Government announced that KEYTRUDA (pembrolizumab) will be subsidised through the Pharmaceutical Benefits Scheme (PBS) for over 10,000 newly eligible Australians with advanced or metastatic cancers from 1 September 2026.
Aug 27, 2026, 20:45 UTC
The University of Queensland commemorates the 20th anniversary of the first dose of the HPV vaccine (Gardasil 9), developed by Ian Frazer and Jian Zhou, which has been administered over 600 million times worldwide and is credited with helping to end cervical cancer in Australia.
Source:Aug 25, 2026, 09:21 UTC
Bank of New York Mellon Corp reduced its stake in Merck & Co., Inc. by 2.0% during the quarter, selling 373,190 shares, as disclosed in its Form 13F filing.
Source:Aug 25, 2026, 09:21 UTC
Bellars Harris Wealth Management LLC disclosed a new minority stake in Merck & Co., Inc. by purchasing 79,847 shares valued at approximately $10.26 million, as reported in its Form 13F filing.
Source:Aug 25, 2026, 07:57 UTC
ABN AMRO Bank N.V. reduced its stake in Merck & Co., Inc. by 7.6% during the quarter, selling 11,149 shares, according to its Form 13F filing.
Source:Aug 16, 2026, 13:46 UTC
Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.
Source:Aug 15, 2026, 15:46 UTC
Richard R. DeLuca, Executive Vice President and President of Merck Animal Health, sold 45,320 shares of Merck & Co., Inc. common stock over three days from August 10 to August 12, 2026, totaling approximately $5,942,369.
Source:Aug 10, 2026, 18:57 UTC
President Trump is expected to sign an executive order recommending the split of the MMR combination vaccine into three separate vaccines and the administration of childhood vaccines at separate visits.
Aug 8, 2026, 23:00 UTC
Uniquity Bio appointed Jason Moore as senior vice president of regulatory and quality.
Source:Aug 7, 2026, 03:07 UTC
Merck & Co.'s Ebola vaccine and Gilead Sciences' antiviral drug are set for wider use in eastern Democratic Republic of Congo to combat the fastest-growing Ebola outbreak on record.
Source:Aug 6, 2026, 10:45 UTC
The U.S. FDA accepted Merck's supplemental Biologics License Application for ENFLONSIA (clesrovimab-cfor) to expand its RSV lower respiratory tract disease indication to include children under two years at increased risk for severe RSV through their second season.
Source:Aug 4, 2026, 23:40 UTC
McDonald's and Merck reported earnings that beat analyst expectations.
Source:Aug 4, 2026, 15:16 UTC
Merck incurred costs related to its acquisition of Turnstone Biologics, a leukemia drug developer, which impacted its full-year EPS guidance.
Source:Aug 4, 2026, 10:34 UTC
Merck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.
Aug 4, 2026, 10:30 UTC
Merck & Co., Inc. announced its financial results for the second quarter of 2026.
Aug 3, 2026, 18:02 UTC
Merck & Co. presented its HIV treatment and prevention strategy at an investor event, highlighting Phase III results for a once-weekly oral HIV regimen and plans for a monthly oral PrEP candidate.
Source:Jul 31, 2026, 18:10 UTC
Merck acquired Terns Pharmaceuticals and Cidara Therapeutics to broaden its oncology and virology portfolios.
Source:Jul 31, 2026, 18:10 UTC
Merck launched subcutaneous Qlex, extending the lifecycle of Keytruda.
Source:Jul 31, 2026, 14:30 UTC
Rappta Therapeutics, founded by Goutham Narla, was acquired by Merck, which will develop its treatment for endometrial and lung cancer.
Source:Jul 31, 2026, 09:15 UTC
Universal Corporation Limited (UCL) of Kikuyu, Kenya, was selected by Merck as one of seven manufacturers worldwide to produce alimatravir, an experimental once-monthly HIV prevention pill, under a licensing agreement announced at the 26th International Aids Conference in Rio de Janeiro.
Source:Jul 29, 2026, 15:04 UTC
Merck announced its fourth-quarter 2026 dividend on July 29, 2026.
Source:Jul 27, 2026, 01:54 UTC
Aurobindo Pharma Ltd has entered into a non-exclusive voluntary licensing agreement with MSD (Merck & Co., Inc.) for an HIV drug.
Source:Jul 24, 2026, 19:38 UTC
Qnity Electronics, Inc. appointed Katherine (Kate) Dei Cas as President of its Semiconductor Technologies business segment, effective August 3.
Source:Jul 24, 2026, 10:45 UTC
Merck has licensed its experimental oral HIV drug to generic manufacturers in 129 countries.
Jul 21, 2026, 14:00 UTC
Gilead Sciences and Merck & Co. announced phase 3 clinical trial results for their two-drug combination lenacapavir and islatravir, positioning it as the first complete weekly oral HIV treatment.
Source:Jul 20, 2026, 01:05 UTC
Merck Animal Health's needle-free intradermal vaccine Porcilis® M Hyo ID ONCE® received approval from China's Ministry of Agriculture and Rural Affairs for the prevention of disease caused by Mycoplasma hyopneumoniae infection in pigs.
Source:Jul 17, 2026, 00:00 UTC
GSK discontinues development of camlipixant, an experimental chronic cough medicine, after mixed Phase 3 data.
Jul 16, 2026, 17:49 UTC
The U.S. Food and Drug Administration approved Merck's first-of-its-kind cholesterol-lowering pill Lipfendra for high-risk patients.
Jul 2, 2026, 02:30 UTC
Merck Animal Health will launch Senstan® in China.
Source:Jun 9, 2026, 20:36 UTC
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir.
Source: